BackDexcom Overview
Dexcom Inc

Dexcom Target Price

Analysts' average 12-month price target for Dexcom is $88.

Get informed when a big investor buys or sells

+ Follow

Share Price

$89.6

Average Target Price

$87.682.1% downside

25 analysts in the last 4 months

High: $105 | Low: $64

Analyst Recommendations

No recommendations in the last 4 months.

Revenue & Income Forecast

Analysts' Target Prices

DateAnalystPrice TargetCurrent Upside/Downside
2026-08-04Argus ResearchSteve Silver$967.1% upsideOpen
2026-08-03Canaccord Genuity$900.4% upsideOpen
2026-08-03RBC Capital$900.4% upsideOpen
2026-07-31Raymond JamesJayson Bedford$944.9% upsideOpen
2026-07-31Piper SandlerMatt O'Brien$956% upsideOpen
2026-07-31Robert W. Baird$10517.2% upsideOpen
2026-07-31BTIGMarie Thibault$900.4% upsideOpen
2026-07-31Truist FinancialRichard Newitter$933.8% upsideOpen
2026-07-31Stifel NicolausJonathan Block$956% upsideOpen
2026-07-28UBS$967.1% upsideOpen
2026-07-16Truist Financial$872.9% downsideOpen
2026-06-23Deutsche Bank$864% downsideOpen
2026-06-15Piper SandlerMatt O'Brien$881.8% downsideOpen
2026-06-10UBS$956% upsideOpen
2026-06-09Mizuho SecuritiesAnthony Petrone$855.1% downsideOpen
2026-06-08Raymond James$911.6% upsideOpen
2026-06-05Stifel NicolausJonathan Block$900.4% upsideOpen
2026-05-18Canaccord Genuity$828.5% downsideOpen
2026-05-18BarclaysMatt Miksic$6428.6% downsideOpen
2026-05-01Bernstein$7714.1% downsideOpen
2026-05-01Robert W. Baird$8010.7% downsideOpen
2026-05-01Mizuho SecuritiesAnthony Petrone$7516.3% downsideOpen
2026-05-01Raymond James$819.6% downsideOpen
2026-05-01Canaccord Genuity$10011.6% upsideOpen
2026-05-01Barclays$6725.2% downsideOpen
2026-02-13Robert W. Baird$872.9% downsideOpen
2026-02-13Mizuho SecuritiesAnthony Petrone$900.4% upsideOpen
2026-02-13Canaccord Genuity$956% upsideOpen
2026-02-13Barclays$7219.6% downsideOpen
2026-01-12Barclays$7120.8% downsideOpen
2026-01-09Bernstein$864% downsideOpen
2025-12-17Mizuho Securities$7812.9% downsideOpen
2025-12-16Leerink PartnersMike Kratky$922.7% upsideOpen
2025-12-02Morgan StanleyPatrick Wood$7516.3% downsideOpen
2025-11-10Morgan Stanley$6329.7% downsideOpen
2025-11-03BernsteinLee Hambright$846.2% downsideOpen
2025-11-03Barclays$8010.7% downsideOpen
2025-10-31Piper SandlerMatt O'Brien$7516.3% downsideOpen
2025-10-31RBC Capital$855.1% downsideOpen
2025-10-31Robert W. Baird$828.5% downsideOpen
2025-10-31Wells Fargo$933.8% upsideOpen
2025-10-31Canaccord GenuityWilliam Plovanic$9910.5% upsideOpen
2025-10-21Piper SandlerMatt O'Brien$10011.6% upsideOpen
2025-10-15Truist FinancialRichard Newitter$944.9% upsideOpen
2025-09-26Robert W. Baird$900.4% upsideOpen
2024-10-08RBC CapitalShagun Singh$12033.9% upsideOpen
2024-08-22Stifel NicolausMathew Blackman$10011.6% upsideOpen
2024-08-16RBC CapitalShagun Singh$13045.1% upsideOpen
2024-07-29BarclaysMatt Miksic$11326.1% upsideOpen
2024-07-26OppenheimerSteven Lichtman$11528.3% upsideOpen

Dexcom (DXCM) FAQ

Dexcom's target price stands at $88. Stockcircle updates this page with the newest filings so you can track how the metric evolves quarter by quarter.

The Street's average target of $88 for DXCM implies 2.1% downside versus today's price ($89.6). Positive implied upside usually reflects optimism on growth or margins, while a large downside can signal valuation or fundamental concerns. Check recommendation mix and recent target changes for more context.

The history chart shows how Dexcom's target price evolved across reporting periods, while the comparison chart places DXCM next to similar companies. Use both: a rising metric that still lags peers tells a different story than a rising metric that already leads the group. Growth charts, when available, highlight acceleration or slowdown.

Yes — within Healthcare, target price is commonly used to spot outliers. Dexcom's reading of $88 is a starting point; confirm whether differences come from growth, margins, accounting choices, or one-time items before treating an outlier as a buy or sell signal.